[Too good to be true].
作者信息
Brox Jens Ivar
机构信息
Ryggseksjonen, Ortopedisk avdeling, Oslo universitetssykehus, Rikshospitalet.
出版信息
Tidsskr Nor Laegeforen. 2011 Nov 15;131(22):2228-9. doi: 10.4045/tidsskr.11.0841.
PMID:22085945
Abstract
摘要
相似文献
1
[Too good to be true].
Tidsskr Nor Laegeforen. 2011 Nov 15;131(22):2228-9. doi: 10.4045/tidsskr.11.0841.
2
Exposing conflicts of interest and complications of rhBMP-2.
Neurosurgery. 2011 Oct;69(4):N21-2. doi: 10.1227/01.neu.0000405599.24202.aa.
3
Medtronic submits full data on spinal protein to independent scrutiny.
BMJ. 2011 Aug 30;343:d5484. doi: 10.1136/bmj.d5484.
4
Folly of FDA-approval studies for bone morphogenetic protein.
Spine J. 2011 Jun;11(6):495-9. doi: 10.1016/j.spinee.2011.05.009.
5
Resetting standards for sponsored research: do conflicts influence results?
Spine J. 2011 Jun;11(6):492-4. doi: 10.1016/j.spinee.2011.05.001.
6
A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors.
Spine J. 2011 Jun;11(6):463-8. doi: 10.1016/j.spinee.2011.06.001.
7
Bone morphogenetic protein and fusion.
J Neurosurg Spine. 2007 Apr;6(4):378-9; author reply 379-80. doi: 10.3171/spi.2007.6.4.378.
8
A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research.
Spine J. 2012 Oct;12(10):877-80. doi: 10.1016/j.spinee.2012.11.002.
9
First reviews are published that are based on the "totality of the evidence".
BMJ. 2013 Jun 17;346:f3909. doi: 10.1136/bmj.f3909.
10
Re: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.
Spine J. 2011 Aug;11(8):804; author reply 804-5. doi: 10.1016/j.spinee.2011.08.001.
Zotero 插件